期刊文献+

索利那新对压力性尿失禁患者性功能的影响

The Effect of Solifenacin on Sexual Function in Women with Stress Urinary Incontinence
下载PDF
导出
摘要 目的研究索利那新对女性压力性尿失禁(SUI)患者性功能的影响及相关因素。方法 2013年12月~2014年5月接受索利那新治疗的94例患者纳入研究,采用盆腔器官脱垂-尿失禁患者性功能(PISQ-12)问卷对患者进行随访评分。结果 81例(86.1%)患者回答了PISQ-12问卷,服药前前PISQ总评分为(83.9±10.6)min,服药后为(84.6±15.3)min,差异无统计学意义(P〉0.05)。但服药前后情感因素评分为(27.1±10.7)min和(30.5±6.7)min,两者比较具有显著性差异(P〈0.05)。溢尿组性生活改善率为67.5%(25/37),无溢尿组性生活改善率为22.7%(10/44),两者比较,差异有统计学意义(P〈0.01)。重度组PISQ总评分升高率为67.5%(27/35),中度组PISQ总评分升高率为32.6%(15/46),两者比较,差异有统计学意义(P〈0.05)。结论索利那新对性生活中不自主溢尿者和尿失禁重度患者,服药后症状缓解,可显著提高性生活质量。 OBJECTIVE To evaluate postoperative effects of solifenacin on sexual function of female patients with genuine stress urinary incontinence. METHODS 94 sexually active patients who underwent TVT-O procedure between December 2013 and May 2014 in our urological center were included in this study. During the follow-up period,they were evaluated their sexual function with the Pelvic Organ Prolapse / Incontinence Sexual Questionnaire-12( PISQ-12). RESULTS 81 patients( 86. 1%) completed the questionnaire. The total average scores of PISQ-12were( 85. 3 ± 10. 6) min and( 84. 6 ± 16. 5) min before and after treat,respectively,and there was no significant difference( P〉0. 05); however,the behavioral emotional domain scores increased significantly from( 27. 1 ± 10. 7)min to( 30. 5 ± 6. 7) min( P〈0. 05); The sexual function improvement rats were 67. 5%( 37 /49) and 22. 7%( 9 /35) in patients with and without urine leakage during sexual intercourse,respectively. Similarly,most of patients with serious SUI could get sexual function improvement. CONCLUSION The patients with involuntary urine leakage during sexual intercourse or serious symptom may improve their sexual function due to the leakage alleviation.
出处 《海峡药学》 2015年第10期88-89,共2页 Strait Pharmaceutical Journal
关键词 压力性尿失禁 索利那新 性功能 Solifenacin stress urinary incontinence Sexual function
  • 相关文献

参考文献5

  • 1Zhu L,Lang J,Liu C,et al.The epidemiological study of women with urinary incontinence and risk factors for stress urinary incontinence in China[J].Menopause,2009,16(4):831-836.
  • 2Dalpiaz O,Kerschbaumer A,Mitterberger M,Pinggera GM,Colleselli D,Bartsch G,Strasser H.Female sexual dysfunction:A new urogynaecological research field[J].BJU Int,2008;101:717-21.
  • 3Rogers RG,Kammerer-Doak D,Villan'eal A,et a1.A new instrument to measure sexual function in women with urinary incontinence or pelvic organ prolapse[J].Am J Obstet Gynecol,2001,184:552-558.
  • 4Kocjancic E,Crivellaro S,Oyama IA,Singla A,Ranzoni S,Carone R,Manassero A,Gontero P,Frea B.Transobturator tape in the management of female stress incontinence:Clinical outcomes at medium term follow-up.Urol Int,2008;80:275-8.
  • 5吴士良,肖云翔,段继宏,丁强,孙颖浩,黄翼然,宋波,蔡松良,那彦群.索利那新治疗尿急及急迫性尿失禁的有效性和安全性分析[J].中华泌尿外科杂志,2009,30(9):630-634. 被引量:71

二级参考文献16

  • 1Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function, report from the standardisaton subcommittee of the International Continence Society. Neurourol Urodyn, 2002, 21: 167-178.
  • 2Rovner ES, Wein AJ. Incidence and prevalence of overactive bladder. Curr Urol Rep, 2002, 3:434- 438.
  • 3Irwin DE, Milsom I, Kopp Z, et al. Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries. BJU Int, 2006, 97: 96-100.
  • 4Abrams P, Andersson KE. Muscarinic receptor antagonists for overactive bladder. BJU Int, 2007, 100: 987-1006.
  • 5Ikeda K, Kobayashi S, Suzuki M, et al. M3 receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. N-S Arch Pharmacol, 2002, 366: 97-103.
  • 6Ohtake A, Ukai M, Hatanaka T, et al. In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats. Eur J Pharmaeol, 2004, 492:243- 250.
  • 7Kobayashi S, Ikeda K, Miyata K. Comparison of in vitro selectivity profiles of solifenacin succinate (YM905) and current antimuscarinic drugs in bladder and salivary glands: a Ca2+ mobilization study in monkey cells. Life Sci, 2004, 74: 843-853.
  • 8Smulders RA, Krauwinkel WJ, Swart PJ, et al. Pharmacokinetics and safety of solifenacin succinate in healthy young men. J Clin Pharmacol, 2004, 44:1023- 1033.
  • 9Chapple CR, Arano P, Bosch JL, et al. Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. BJU Int, 2004, 93: 71-77.
  • 10宋波,杨勇,廖利民.膀胱过度活动症诊断治疗指南∥那彦群.中国泌尿外科疾病诊断治疗指南.北京:人民卫生出版社,2007:330.

共引文献70

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部